cagrilintide novo nordisk with semaglutide fda Submits CagriSema for FDA Approval for Obesity Treatment Efficacy and safety of once-weekly
Description
Three 30mg vials covers 90mg, sufficient for weeks 9-16 with some remaining

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, originally developed to help manage type 2 diabetes

Revised 2023
Product Info Molecular formula: N/A (experimental peptide) Molecular weight: N/A Purity: 99%+ Sequence: N/A Most standard lyophilized research vials are commonly prepared using 2mL of bacteriostatic water unless otherwise specified directly on the product page or vial label
01022-6/asset/a38873d9-5999-4e60-a3fc-c2fd1cbeca3d/main.assets/gr2_lrg.jpg)